HSHHSH Health Technology Supplier Hub
Home › Suppliers › Amwell › Risk

Amwell: risk summary

Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.

Financial

Latest full-year results from official filings.

FY2025 revenue $249.3m (-2.0%); operating margin -42.2%; net loss $95.7m.

No debt; $182.3m cash.

Researched 8 Nov 2026

Adverse media

Credible news about incidents, disputes, legal action or restructuring in the last 24 months.

Feb 2026: Amwell guided 2026 revenue to $195–205m, down from $249.3m in 2025, after cutting back products and selling its virtual psychiatric care business; it said it was considering further divestitures of legacy assets.

Researched 10 Nov 2026

Cyber & information governance

Data breaches, cyber incidents, regulator action and assurance status.

Sep 2026: A proposed $2.04m class action settlement was reported resolving claims that Amwell's LiveHealth Online booking tool disclosed users' medical information to third parties without permission; Amwell has not admitted wrongdoing. NHS DSPT status not yet checked.

Researched 10 Nov 2026

Regulatory & clinical safety

Recalls, safety notices, regulator action and clinical safety concerns.

Telehealth platform supplier; no regulatory or clinical safety actions involving Amwell found in HSH's search of the last 24 months.

Researched 10 Nov 2026

Contract performance

Contract delivery, go-lives, terminations and disputes.

Aug 2026: The US Defense Health Agency issued an intent to award Amwell a sole-source contract, with terms still under negotiation; DHA had earlier dropped Amwell's behavioural health and automated care programmes from a 2025 extension owing to budget limits.

Researched 10 Nov 2026